
Program Manager - Drug Development
Partner with Team Leaders to manage the development and execution of program team strategy. Establish and maintain functionally integrated program schedules in accordance with established structures to enable accurate project analyses, identification of critical path activities and areas of resource constraint. Assess program risk and support mitigation planning and tracking. Independently identify and manage program objectives, work plans, timelines, budgets, providing formal and informal status updates to stakeholders as needed. Challenge assumptions and provide recommendations to improve processes and outcomes. Contribute to development efforts by leveraging network of experts and experienced vendors to solve drug development challenges. Facilitate and document program team meetings, cross-functional communication and decision making, ensuring alignment with internal functional groups and leadership. Develop relationships with key functional stakeholder groups and their leadership across the organization to support the execution of program goals.
PMP Certification highly desired
Experience managing global drug development efforts
12+ years of multi-diciplinary experience in the pharmaceutical/biotechnology industry
Experience with both early and late phase program management including IND/CTA submissions
Project Management
Time Management
Analytical skills
Presentation skills
Multitasking
Detail Oriented
Communication Skills
Problem-Solving
self-directed
According to JobzMall, the average salary range for a Program Manager - Drug Development in 12780 El Camino Real, San Diego, CA 92130, USA is $150,000 to $200,000 per year. The salary range may vary depending on the type of organization, the size of the organization, and the experience of the Program Manager.
Apply with Video Cover Letter Add a warm greeting to your application and stand out!
Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD). The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

Get interviewed today!
JobzMall is the world‘ s largest video talent marketplace.It‘s ultrafast, fun, and human.
Get Started